Elevated Risk of New-Onset Thyroid Disease Associated With SARS-CoV-2 Infection: A 4.5-Year Observational Study
The Journal of Clinical Endocrinology & Metabolism · 2026
DOI: 10.1210/clinem/dgaf688 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2026. Verfasst von Shiv Mehrotra-Varma und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Montefiore Health System and Albert Einstein College of Medicine, Bronx, NY 10461, USA. Hauptthemen laut MEDLINE: COVID-19, Thyroid Diseases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 48 Literaturangaben.
Abstract (Originalsprache)
Context
Thyroid disease has been reported as a complication associated with acute SARS-CoV-2 infection.
Objective
This study evaluated the long-term risk of incident thyroid dysfunction after COVID-19 in patients without preexisting thyroid disease.
Methods
Patients without prior thyroid disease were grouped into 15 372 individuals hospitalized with COVID-19, 41 757 nonhospitalized individuals with COVID-19, 343 348 contemporary COVID-negative controls (March 1, 2020-August 17, 2024), and 171 141 historical controls (January 1, 2016-December 31, 2019) within the Montefiore Health System. Outcomes included new-onset thyroid disease, hypothyroidism, hyperthyroidism, and other/unspecified thyroid disease, and thyrotropin (TSH), free 3,5,3′-triiodothyronine (FT3), and free thyroxine (FT4) levels. The primary analysis used Cox regression with inverse probability weighting (IPW). Sensitivity analyses included multivariate adjustment, 1:1 propensity score matching, and comparisons with historical controls.
Results
Compared to contemporary COVID-negative controls, patients hospitalized for COVID-19 had significantly higher risk of all thyroid disease (IPW-adjusted hazard ratio (HR) = 2.11 [2.03-2.19]), hypothyroidism (HR = 2.02 [1.92-2.12]), hyperthyroidism (HR = 2.31 [2.13-2.50]), and other/unspecified thyroid disease (HR = 2.27 [2.12-2.43]). Nonhospitalized COVID-positive patients also had increased risk of all thyroid disease (HR = 1.40 [1.35-1.46]), hypothyroidism (HR = 1.37 [1.31-1.43]), hyperthyroidism (HR = 1.56 [1.45-1.68]), and other/unspecified thyroid disease (HR = 1.42 [1.34-1.51]). Sensitivity analyses were consistent with the main findings. Estimates of risks were attenuated in the nonhospitalized cohort when compared to historical controls.
Conclusion
SARS-CoV-2 infection is associated with an increased risk of all forms of new-onset thyroid disease investigated both in hospitalized and nonhospitalized patients. These findings suggest that enhanced screening for thyroid dysfunction may be warranted among individuals recovering from COVID-19.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiology, Montefiore Health System and Albert Einstein College of Medicine, Bronx, NY 10461, USA.
- Center for Health Data Innovation, Montefiore Health System and Albert Einstein College of Medicine, Bronx, NY 10461, USA.
ORCID-Profile: Shiv Mehrotra-Varma, Tim Q Duong
Zitieren
APA
Mehrotra-Varma, S., Hadidchi, R., Henry, S. S., Nguyen, H. Q., Mehrotra-Varma, J., Coard, M. C., Changela, S., Collins, J., & Duong, T. Q. (2026). Elevated Risk of New-Onset Thyroid Disease Associated With SARS-CoV-2 Infection: A 4.5-Year Observational Study. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaf688
Vancouver
Mehrotra-Varma S, Hadidchi R, Henry SS, Nguyen HQ, Mehrotra-Varma J, Coard MC, et al. Elevated Risk of New-Onset Thyroid Disease Associated With SARS-CoV-2 Infection: A 4.5-Year Observational Study. The Journal of Clinical Endocrinology & Metabolism. 2026. doi:10.1210/clinem/dgaf688
BibTeX
@article{MehrotraVarma2026,
author = {Mehrotra-Varma, Shiv and Hadidchi, Roham and Henry, Sonya S and Nguyen, Hien Quang and Mehrotra-Varma, Jai and Coard, Michael C and Changela, Sagar and Collins, Jessilin and Duong, Tim Q},
title = {Elevated Risk of New-Onset Thyroid Disease Associated With SARS-CoV-2 Infection: A 4.5-Year Observational Study},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2026},
doi = {10.1210/clinem/dgaf688}
}
EUVIMED